Recruiting

Computational Modeling

Sponsor:

Icahn School of Medicine at Mount Sinai

Code:

NCT07011901

Conditions

Obsessive Compulsive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Exposure and Response Prevention

Study Details

Brief summary:

Psychiatric disorders characterized by compulsivity, such as obsessive-compulsive disorder (OCD), result in considerable functional impairment and many individuals do not respond to gold-standard treatments. Compulsivity has long been thought to occur due to exaggerated habits and reduced goal-directed control, although more recently, this conceptualization of compulsivity as an imbalance of two cognitive systems has been challenged as overly narrow. This study will recruit 100 individuals (50 adults diagnosed with OCD, 50 healthy controls) and leverage the measurement precision offered by theory-driven computational modeling in combination with electroencephalogram (EEG) to go beyond this binary theory of compulsivity, revealing how more complex interactions of neurocognitive subcomponents contribute to compulsivity-information that could ultimately lead to improved treatment personalization and clinical outcomes.

Conditions

Obsessive Compulsive Disorder

Study ID

NCT07011901

Start date

Jul 9, 2025

Status verified date

Oct, 2025

Completion date

Mar 31, 2030

Anticipated

Primary completion date

Mar 31, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

Participants must be:

  • between the ages 18-55 years old
  • English-speaking
  • right-handed
  • able to provide consent

Exclusion Criteria:

Individuals diagnosed with OCD will be excluded if:

  • they meet diagnostic criteria for certain other psychiatric disorders
  • are taking psychiatric medication or have received behavioral treatment for OCD within a certain timeframe
  • if it is unsafe for them to participate in research

Healthy control participants will be excluded if:

  • they have a current psychiatric disorder
  • a lifetime history of certain psychiatric disorders
  • are taking psychiatric medication or have in the past
  • have a parent or sibling who has been diagnosed with OCD
  • if it is unsafe for them to participate in research

Study Design

Enrollment

100 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Participants diagnosed with OCD

All participants diagnosed with Obsessive Compulsive Disorder (OCD) who enroll in this study will receive 17 sessions of exposure and response prevention, a specialized cognitive behavioral therapy for OCD, over the course of 10 weeks.

no intervention: Healthy controls

Individuals who do not have a current or lifetime psychiatric diagnosis will not receive any treatment.

Interventions

Exposure and Response Prevention

Exposure and response prevention (EX/RP) is the gold-standard behavioral treatment for OCD. It involves confronting the content of obsessions (distressing thoughts, images, or impulses) and resisting the urge to engage in compulsions (observable behaviors or mental acts that are repeated to reduce the anxiety/distress associated with compulsions).

Primary outcome measure

  • Yale Brown Obsessive Compulsive Scale [ Time Frame: Week 1, Week 5, Week 10 ]

Central Contacts and Locations

Central contacts

Amy Rapp, Ph.D.

212-241-5288OCDResearch@mssm.edu

Locations

Icahn School of Medicine at Mount Sinai

Recruiting

New York, New York, United States, 10029

Principal Investigator:

Amy Rapp

More Information

Sponsor

Icahn School of Medicine at Mount Sinai

Last update posted

Oct 23, 2025

Last verified

Oct, 2025

Keywords

  • Obsessive Compulsive Disorder
  • Exposure and response prevention
  • Cognitive Behavioral Therapy
  • Electroencephalogram

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai on 2025-10-23.